Ursodex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ursodex

Defining Ursodex: Key Drug Facts and Identity

Property Description
Active Ingredient Ursodeoxycholic Acid (UDCA)
Form Oral Capsule or Tablet
Pharmacological Class Cholagogue; Cholelitholytic Agent
General Purpose Management of chronic liver and gallbladder conditions
Origin Semi-synthetic (derived from a natural bile acid)

Ursodex is a prescription medicine containing ursodeoxycholic acid (UDCA), the internationally recognized active ingredient. It is classified pharmacologically as a cholagogue and cholelitholytic agent, often supplied for oral administration as a capsule or tablet.

UDCA is part of the therapeutic strategy for managing certain hepatobiliary disorders. Its function in stabilizing cell membranes and reducing bile acid toxicity is well-established, a benefit supported by decades of pharmacological studies. Research confirms the drug's established role in protecting liver cells and balancing essential bile compounds.

Is Ursodex Natural or Synthetic?

Although ursodeoxycholic acid occurs naturally in small quantities in human bile, the UDCA used in pharmaceutical products like Ursodex is produced via a controlled, high-purity semi-synthetic process. This ensures the finished medicinal product meets strict regulatory standards for consistency and safety.

What is the Main Purpose of Ursodex?

The primary purpose of Ursodex is the long-term management of specific chronic conditions affecting the liver and gallbladder, such as cholestatic diseases and certain types of cholesterol gallstones. Its general function is to modify the chemical balance within the biliary system to slow disease progression and improve overall organ function.

Regulatory References

  1. Public Assessment Report (URSODEOXYCHOLZUUR STRIDES)

What side effects are possible with Ursodex?

Possible Side Effects and Safety Information

The official safety profile for Ursodex (ursodeoxycholic acid) is structured around categories established by regulatory authorities, detailing the documented side effects and restrictions of use. The majority of reported adverse reactions are classified by official documents as common and involve the gastrointestinal system.

Frequency-Classified Adverse Reactions

The most frequently cited side effects in regulatory documents are generally common and often dose-dependent. Uncommon and rare effects are also documented across different system-organ classes.

Classification System-Organ Class Examples Listed in Regulatory Documents
Common Gastrointestinal Disorders Diarrhea, Pasty stools
Uncommon Skin and Subcutaneous Tissue Disorders Urticaria (Hives), Pruritus

Serious Adverse Reactions and Safety Constraints

Regulatory labeling documents specific rare and very rare events, particularly related to the hepatobiliary system. Liver function parameters are required to be monitored every four weeks during the first three months of treatment, and periodically thereafter, due to the potential for transient changes in laboratory tests.

Serious adverse reactions documented in the regulatory profile include the calcification of gallstones and the decompensation of hepatic cirrhosis, noted very rarely in patients with Primary Biliary Cholangitis (PBC). The use of Ursodex is contraindicated in patients with acute inflammation of the gallbladder, unremitting biliary obstruction, or a non-functioning gallbladder, as defined by official regulatory texts. These constraints establish the precise boundaries for the medicine's use.

Overdose and Emergency Response

Overdose and When to Seek Help: Ursodex (Ursodeoxycholic Acid)

This section summarizes the official overdose information for Ursodeoxycholic Acid, as documented in governmental regulatory sources. The information is not intended as a substitute for professional medical advice.

Documented Overdose Profile

Official prescribing information indicates that Ursodex generally exhibits low acute toxicity. Cases involving up to fifty times the standard therapeutic dose have been documented with few serious consequences.

Primary Overdose Manifestation Treatment Approach
Diarrhea (most likely sign) Symptomatic management to restore fluid and electrolyte balance
Abdominal Pain Requires monitoring and supportive care

Required Emergency Actions

There is no known specific antidote listed for Ursodex overdose. Management focuses entirely on treating the symptoms.

Immediate actions required by regulatory labeling:

  • Contact a Poison Control Center: Users are instructed to contact their regional poison control center or emergency services for guidance in the event of a suspected overdose.
  • Dose Adjustment: If the key symptom of overdose—persistent or severe diarrhea—occurs, official instructions require the dose to be reduced or the medicine to be discontinued to resolve the effect.

Population Notes: Regulatory documents do not list specific human population considerations (e.g., pediatric or geriatric) related to overdose severity or distinct required management.

Therapeutic Uses of Ursodex

What Ursodex Treats: Main Uses and Benefits

Ursodeoxycholic acid (UDCA), the active compound in Ursodex, is commonly used to help with therapeutic areas concerning the liver and gallbladder. Its core benefit is its role in managing symptoms related to systemic imbalance that often become more disruptive during flare-ups.

UDCA is considered relevant for managing conditions characterized by periods of heightened symptoms, including Primary Biliary Cholangitis (PBC) and for the management of gallstones where dissolution may be appropriate. Its use is relevant when supportive symptom management is appropriate. The treatment helps relieve symptoms related to physical discomfort caused by these conditions.

In clinical scenarios involving acute or unstable symptom patterns, UDCA contributes to easing the overall symptom load. It is applied across domains where additional symptomatic support is needed. A patient-oriented benefit is that this support:

“...offers symptomatic relief that helps patients cope more steadily.”

This agent is often used during phases when symptoms become more noticeable and may assist with managing symptom clusters that create noticeable physiological strain, which contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Symptoms that interfere with daily functioning

Eligibility and Restrictions for Use

Who Can and Cannot Use Ursodex?

Ursodex (ursodeoxycholic acid) is indicated for patients with radiolucent, noncalcified cholesterol gallstones that are less than 20 mm in diameter, particularly when surgical removal is medically contraindicated. It is also approved for preventing gallstone formation in obese patients undergoing rapid weight loss.


Who Cannot Use Ursodex (Contraindications)

Ursodex must not be used by individuals with a known allergy or hypersensitivity to ursodeoxycholic acid or any of its components. It is also strictly contraindicated in patients with the following acute conditions:

  • Unremitting acute cholecystitis
  • Cholangitis or biliary obstruction
  • Gallstone pancreatitis
  • Biliary-gastrointestinal fistula

Important Restrictions and Considerations

Population/Condition Eligibility Status
Pediatric Use Safety and efficacy have not been established.
Stone Composition Not recommended for calcified, radiopaque, or bile pigment stones.
Pregnancy (Early) Not approved due to insufficient data on first-trimester risk.
Hepatic Function Requires monitoring of liver function tests (LFTs); treatment may be stopped if LFTs become clinically significant.
Intestinal Stenosis Risk Requires monitoring for potential obstructive symptoms.

These rules define the official regulatory scope for its use, focusing on patient safety and the physiological requirements for effective treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Ursodeoxycholic Acid (Ursodex) is defined by its effects on drug absorption and its primary therapeutic action.

Restrictions and Contraindicated Effects

Co-administration with estrogenic hormones, including hormonal oral contraceptives, and certain lipid-lowering drugs such as Clofibrate is generally discouraged. These substances may promote the formation of cholesterol gallstones, which counteracts the cholelitholytic effectiveness of Ursodex, as documented in official labeling.


Pharmacokinetic Interactions

Interaction patterns require careful administration timing with certain agents. Bile acid sequestering agents (e.g., Cholestyramine) and aluminum-based antacids (e.g., Aluminum Hydroxide) reduce the intestinal absorption of Ursodex by binding bile acids. To prevent this reduction in exposure, regulatory documents mandate that these agents must be separated by at least 2 hours from Ursodex administration.

Ursodex can also affect the exposure of co-administered medicines. The absorption and plasma concentrations of Ciclosporin may be increased when taken with Ursodex. Conversely, Ursodex has been documented to reduce the plasma peak concentration of agents like Nitrendipine and the therapeutic effect of Dapsone.

Mechanism of Action

How Ursodex Works

The action of Ursodex (Ursodeoxycholic Acid, UDCA) is defined by three complementary mechanistic domains that target the chemical environment, cellular integrity, and secretory capacity of the hepatobiliary system.


Chemical Substitution and Detoxification

The primary mechanism involves competitive displacement where the highly hydrophilic UDCA substitutes a large portion of the body's naturally occurring, more hydrophobic bile acids that are cytotoxic to liver cells. This action chemically detoxifies the entire bile acid pool, which leads to a reduction in the concentration of cytotoxic bile acids and influences the chemical environment within the liver and bile ducts.


Cytoprotection and Secretory Enhancement

At the cellular level, UDCA physically stabilizes the mitochondrial membrane of liver cells, thereby inhibiting the intrinsic apoptotic cascade (cell death) triggered by chemical stress. Concurrently, it upregulates key canalicular transporters (BSEP, MRP2) to increase the active secretion of fluid and bile constituents. This dual effect inhibits the apoptotic cascade while enhancing bile flow and the transport of retained substances.


Biliary Cholesterol Modulation

This mechanism involves modifying the physical chemistry of bile by inhibiting the secretion of cholesterol from the liver and reducing its intestinal absorption. By lowering the cholesterol saturation of bile, the drug increases the bile's capacity to keep cholesterol dissolved. This alters the physicochemical environment, promoting the solubilization of certain cholesterol crystals.

Dosage and Administration Information

Ursodex is administered exclusively by the oral route, available as capsules, tablets, or an oral suspension. The administration protocol is defined based primarily on the clinical purpose.

For the management of chronic conditions such as Primary Biliary Cholangitis (PBC), the adult dose is typically established at 13-15 mg/kg of body weight daily. This regimen is generally initiated in two to four divided doses and is instructed to be taken with food.

For the purpose of gallstone dissolution, a lower weight-based dose, usually 8-12 mg/kg per day, is prescribed. This is a distinct, time-bound course that commonly lasts between six months and two years, with instructions requiring treatment continuation for an additional three to four months after radiological clearance of the stones. In contrast, use for PBC is designed as a long-term, continuous administration pattern.

Tablets must be swallowed whole with liquid. When a precise dose requires breaking a scored tablet, the resulting segments should be consumed unchewed to avoid the product's inherent bitter taste. For pediatric patients, such as those with cystic fibrosis-associated liver disease, a specific weight-adjusted dosing, starting at 20 mg/kg per day in divided doses, is described.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ursodex (Ursodeoxycholic Acid)

The research available for Ursodeoxycholic Acid (Ursodex) has explored its use in several specific conditions. Understanding the type of research conducted, what it measured, and where evidence is still developing is important for contextualizing the available data.


Evidence for Use in Primary Biliary Cholangitis (PBC)

Ursodex was studied for adults diagnosed with Primary Biliary Cholangitis (PBC), a condition characterized by chronic inflammation and damage to the bile ducts. Research for this condition has focused primarily on long-term clinical trials that examined outcomes related to systemic or functional imbalance, such as changes in liver enzyme levels, which are relevant in evidence describing how symptoms are measured. These studies also researched outcomes reflecting long-term disease patterns. Long-term studies describe patterns in the observed populations, reporting measurements of liver function tests over many years. This research has contributed to the broader evidence landscape for PBC. Studies report data related to the time frame over which certain events occurred or disease patterns were observed.


What Is Still Uncertain About Ursodex (Ursodeoxycholic Acid)

A key uncertainty is that long-term outcomes are not fully established regarding sustained observations for all indications. Evidence quality varies across studies, particularly for less common indications or special populations where sample sizes were modest. The study results reflect the specific conditions under which they were conducted; findings describe group patterns, not personal outcomes. For many applications, comparative evidence is lacking against other available treatments, meaning research has not always been conducted to compare findings across different options.

Key Studies & References Ursodeoxycholic acid therapy for patients with primary biliary cirrhosis. A meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Ursodex (FAQ)


Q: What is Ursodex most commonly prescribed for?

Official regulatory documents indicate this medicine is used for two main purposes. One is the long-term management of Primary Biliary Cholangitis (PBC), a chronic liver condition. The other is to dissolve certain types of cholesterol gallstones that are not calcified.


Q: Can Ursodex affect my liver test results?

Official safety information indicates that taking the medicine may be associated with temporary or transient changes in liver function test parameters. Official information notes that monitoring of these blood tests is a recommended precaution during the initial months of use.


Q: What is the main difference between Ursodex and ursodiol?

The main difference is the name used to refer to the drug. The active ingredient in Ursodex is ursodeoxycholic acid, which is the internationally recognized generic name. This generic drug is often referred to by the shortened name, ursodiol.


Q: Is Ursodex considered a high-risk medication?

Regulatory safety documents classify the majority of reported adverse reactions as common and often related to the dosage. Official information notes that medical monitoring of liver function is a documented precaution during the initial period of use.


Q: What age group is Ursodex generally prescribed for?

The medicine is most commonly prescribed for adults. For the general pediatric population, official documents state that safety and efficacy have not been established. However, specific weight-adjusted dosing is outlined in regulatory documents for certain rare pediatric liver conditions.


Q: What kind of research has been done on Ursodex use in children?

Research has been conducted on its use for specific pediatric liver conditions, such as cystic fibrosis-related liver disease and biliary atresia. While this research exists, official documents often note that overall safety and efficacy are not established in the general pediatric population.


Q: What are the typical benefits seen in research studies involving Ursodex?

Studies have primarily focused on measuring changes related to liver function and disease progression. Research has looked at changes in liver enzyme levels, observed long-term disease patterns, and evaluated the drug's function in modifying the bile acid pool.


Q: Are there any long-term effects of Ursodex that people should be aware of?

Regulatory documents list rare, serious long-term safety concerns, such as the calcification of gallstones and, very rarely, hepatic decompensation in patients with advanced liver disease. Research also indicates that long-term outcomes for all uses are not fully established.


Q: How is the effectiveness of Ursodex generally measured in clinical practice?

Effectiveness is generally assessed by tracking changes in the body's chemistry and, if relevant, physical changes in the gallbladder. This typically involves regular liver function blood tests and, when used for gallstone dissolution, periodic visualization of the gallbladder using tools like ultrasound or X-rays.


Q: Is there a generic version of Ursodex available?

Yes, the medicine is available under its chemical or generic name, ursodiol (ursodeoxycholic acid). It is also supplied in several different brand-name formulations.


Q: Does Ursodex cause weight gain or loss?

Regulatory safety data includes post-marketing reports of unusual weight gain or loss among adverse reactions. This means that while these effects have been reported, their frequency and relationship to the medicine are not confirmed as common or uncommon.


Q: Can Ursodex be taken by someone with kidney problems?

Official regulatory documents primarily focus on the use and restrictions related to liver health. However, official information notes that some labels include pre-existing renal disease among conditions requiring specific medical consideration.


Q: What happens if I miss a dose of Ursodex?

Regulatory patient information states that if a dose is missed, the recommended action is to contact a doctor or pharmacist for specific instructions.


Q: Can Ursodex affect blood sugar levels?

Some regulatory documents note a potential interaction with oral diabetes medication. This means the medicine may affect the action of certain drugs used to manage blood sugar. This is a situation where careful monitoring by a healthcare provider is noted in official information.


Q: Is it normal to feel slightly nauseous when starting Ursodex?

Gastrointestinal discomforts, including nausea and vomiting, are listed in official documents as documented adverse reactions. While these effects are noted, they are not always classified as common.


Q: Are there different strengths of Ursodex tablets?

Yes, official drug product information confirms that the medicine is available in different strengths for oral administration. For tablets, examples include 250 mg and 500 mg formulations.


Q: Is Ursodex an anti-inflammatory drug?

Official documents classify the medicine primarily as a cholagogue (a substance that stimulates bile flow) and cholelitholytic agent (a substance that dissolves gallstones). While it is not formally classified as an anti-inflammatory drug, some descriptions of its effects include immunomodulating properties.


Q: Why do official documents mention Ursodex use with X-rays or ultrasounds?

Regulatory documents specify that gallbladder visualization using ultrasound or X-rays is a procedure documented in official guidelines at specific time points after starting treatment for gallstones. This is done to assess the therapeutic progress of stone dissolution and check for any calcification.


Q: Can older adults safely take Ursodex?

Official prescribing information indicates that while studies have not demonstrated problems that limit its usefulness specifically in the elderly, older patients may be more sensitive to the effects of the medicine. Close monitoring is often a consideration for older adults.


Q: What are the main ingredients in Ursodex besides the active one?

Official drug labels list non-active components, also known as excipients, alongside the active ingredient. These non-active ingredients can vary by specific formulation but typically include ingredients like gelatin, starch, and coloring agents.


Q: Does Ursodex interact with common blood thinners?

Official interaction information has documented potential interactions with certain blood-thinning agents (antiplatelets). This documentation suggests that the risk or severity of adverse effects may be increased when taken together.


Q: Is Ursodex a type of hormone replacement?

No. Official documents classify the medicine pharmacologically as a cholagogue (a substance that stimulates bile flow) and cholelitholytic agent (a substance that dissolves gallstones), not a hormone replacement.


Q: Can Ursodex affect my ability to breastfeed?

Official safety information indicates that when the medicine is taken by breastfeeding women, the amount passing into the milk is very low. Based on this, no adverse reactions are expected in breastfed infants, but official information notes that use during breastfeeding is a matter for medical consideration.

How should Ursodex be stored and disposed of?

How to Store and Dispose of Ursodex?

Ursodex (ursodeoxycholic acid) must be stored under specific regulatory conditions to maintain its stability.

Storage Requirements

The medicine should be stored at Controlled Room Temperature (20 C to 25 C), with permitted fluctuations between 15 C and 30 C. It must be kept in a tightly closed container and protected from excessive moisture. All forms of the product must be stored strictly out of the reach of children.

Disposal Instructions

Unused or expired Ursodex, which is not on the regulatory flush list, should be disposed of in household trash. This involves mixing the medicine with an unappealing substance, such as dirt or used coffee grounds, and sealing the mixture in a bag before discarding. Do not flush the product down a toilet or pour it down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ursodex found in:

A-Z Index: